kn046是康宁杰瑞自主研发的pd-l1/ctla-4双特异性抗体，其创新设计包括：采用机制不同的ctla-4与pd-l1单域抗体融合组成，可靶向富集于pd-l1高表达的肿瘤微环境及清除抑制肿瘤免疫的treg。

The approval of anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) antibodies for human use has already resulted in significant improvements in disease outcomes for various cancers, especially melanoma.

2024年1月8日 · Inhibition of overexpression of immune checkpoints such as CTLA-4 receptors has been confirmed as an effective strategy. In cancer immunotherapy, immune checkpoint-blocking drugs can be enhanced...

2021年10月18日 · kn-046是康宁杰瑞自主研发的一款可同时靶向pd-l1和ctla-4的双特异性抗体，其创新设计包括采用机制不同的ctla-4与pd-l1单域抗体融合组成，可靶向富集于pd-l1高表达的肿瘤微环境及清除抑制肿瘤免疫的treg。

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an immune checkpoint molecule that is mainly expressed on activated T cells and regulatory T (Treg) cells that inhibits T-cell activation and regulates immune homeostasis. Due to the crucial functions of ...

2023年8月21日 · 近年来，针对细胞毒性 T 淋巴细胞相关蛋白4 (CTLA-4)、程序性死亡[蛋白]-1 (PD-1)及其配体- 1（PD-L1）等免疫检查点相关抑制剂在肿瘤的免疫治疗方面取得了一定进展，开启了肿瘤治疗的新时代。 本文就CTLA-4单抗在晚期实体肿瘤中的临床治疗进展进行综述，以期为肿瘤的免疫治疗提供参考。 1 免疫检查点抑制剂及其作用机制. 免疫检查点是维持自身免疫稳态的免疫调节因子，可调节机体免疫应答[3]。 正常情况下，肿瘤细胞使部分免疫检查点失活，造 …

2018年4月18日 · Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of naïve T cells in the lymphoid organs. Recently, we reported th …

2018年3月28日 · Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

2025年3月19日 · Investigating anti-CTLA-4 Abs with pH-sensitive binding, Zhang, Li, and Yan et al. found that only some pH-sensitive ipilimumab variants enhanced the therapeutic index. Ipi13, which retained binding to CTLA-4 at pH 6.0, maintained colocalization with CTLA-4 at the late endosomes and lysosomes, resulting in lysosomal degradation of CTLA-4 and no ...

Upon administration, anti-CTLA-4 monoclonal antibody GIGA-564 targets and binds to CTLA-4, and may induce Fc receptor (FcR) signaling. This may deplete regulatory T cells (Tregs) in the tumor microenvironment (TME), decrease the proliferation of the remaining Tregs in the TME, and reactivate antitumor immune responses.